Stockscreener 앱 받기
2.29
13.26%
-0.35
시간 외 거래:
2.74
0.45
+19.65%
전일 마감가:
$2.64
열려 있는:
$2.55
하루 거래량:
77,664
Relative Volume:
1.99
시가총액:
$3.22M
수익:
-
순이익/손실:
$-11.28M
주가수익비율:
-0.7608
EPS:
-3.01
순현금흐름:
$-9.78M
1주 성능:
-26.60%
1개월 성능:
-57.04%
6개월 성능:
-34.22%
1년 성능:
-80.98%
1일 변동 폭
$2.24
$2.5555
1주일 범위
$2.19
$3.58
52주 변동 폭
$2.118
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
명칭
Ensysce Biosciences Inc
전화
(858) 263-4196
주소
7946 IVANHOE AVENUE, LA JOLLA
ENSC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.29 | 3.22M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
Ensysce Biosciences corrects SEC filing omission By Investing.com - Investing.com South Africa
Ensysce Biosciences corrects SEC filing omission - Investing.com India
Ensysce Biosciences raises $1.1 million in stock sale By Investing.com - Investing.com South Africa
Ensysce Biosciences raises $1.1 million in stock sale - Investing.com
Ensysce Raises Fresh Capital: Strategic $1.1M Investment Powers Next-Gen Pain Drug Pipeline - Stock Titan
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting - ACCESS Newswire
(ENSC) On The My Stocks Page - news.stocktradersdaily.com
Ensysce Biosciences Advances in Opioid Innovation - TipRanks
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Revolutionary Opioid Safety Technology Takes Center Stage at PAINWeek 2025 - StockTitan
How the (ENSC) price action is used to our Advantage - news.stocktradersdaily.com
Zacks Small Cap Issues Negative Forecast for ENSC Earnings - Defense World
Ensysce Biosciences (ENSC) Projected to Post Earnings on Friday - Defense World
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - EIN News
When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St
Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Ensysce Biosciences, Inc. SEC 10-K Report - TradingView
Ensysce Biosciences Narrows Losses to $8M, Secures FDA Breakthrough Status - StockTitan
(ENSC) Long Term Investment Analysis - Stock Traders Daily
Ensysce Biosciences to Present Pain Management Innovations at ROTH Conference - StockTitan
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids - Marketscreener.com
Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website - ACCESS Newswire
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results - ACCESS Newswire
Ensysce Biosciences Regains Compliance with Nasdaq - ACCESS Newswire
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering - ACCESS Newswire
How To Trade (ENSC) - Stock Traders Daily
Revolutionary Pain Management: This New Opioid Actually Prevents Overdose - StockTitan
When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)? - Yahoo Finance
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic - ACCESS Newswire
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium - ACCESS Newswire
Ensysce Biosciences Receives Positive Nasdaq Listing Determination - ACCESS Newswire
Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit - ACCESS Newswire
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate - ACCESS Newswire
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection - ACCESS Newswire
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR - NEWSnet
Ensysce reports overdose protection in drug trial - Investing.com
Ensysce's PF614-MPAR Shows Breakthrough Overdose Protection in Phase 1b Opioid Trial - StockTitan
Biotech Steals The Show Following $14 Million Grant Announcement - MSN
Ensysce's Breakthrough Pain Drug Gets FDA Special Status; Secures $23.7M Funding Boost - StockTitan
Ensysce Biosciences (NASDAQ:ENSC) Shares Down 5.6% – Should You Sell? - Defense World
Ensysce Biosciences Regains Full Compliance with Nasdaq - Financial Content
Ensysce Biosciences Secures Critical Supply Deal for Breakthrough Overdose Protection Drug Development - StockTitan
Ensysce Biosciences Inc (ENSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):